Cybin Hosting Research and Development Briefing on November 8, 2021 Post published:November 2, 2021 Post category:Press Release
Small Pharma Reports Second Quarter Highlights Post published:November 1, 2021 Post category:Press Release
atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial for Novel Treatment of Cognitive Impairment Associated with Schizophrenia Post published:November 1, 2021 Post category:Press Release
Red Light Holland Appoints New Chief Financial Officer Post published:November 1, 2021 Post category:Press Release
PharmaDrug Expands Product Offering to Prepare for Potential Adult Use Market in Germany Post published:November 1, 2021 Post category:Press Release
Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study Post published:November 1, 2021 Post category:Press Release
MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform Post published:October 28, 2021 Post category:Press Release
Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery Program Post published:October 28, 2021 Post category:Press Release
Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program Post published:October 28, 2021 Post category:Press Release
MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias Post published:October 27, 2021 Post category:Press Release